West Pharmaceutical (WST) Upgraded to Strong Buy: Here's Why
West Pharmaceutical (WST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
West Pharmaceutical Services: Low Debt, High Profit, And A Waning Destocking Problem
My estimations suggest that the U.S. government cuts to its healthcare system will not have a significant negative impact on West Pharmaceutical's revenues. In Q2 2025, the company's revenues increased by 9.17%, suggesting that the destocking effect is vanishing. The company has low debt levels, achieving a liabilities-to-assets ratio of 25.90% in Q2 2025. Additionally, it achieved a 17.03% net profit margin in 2024.
West Pharmaceutical Services, Inc. (WST) Q2 2025 Earnings Call Transcript
West Pharmaceutical Services, Inc. (NYSE:WST ) Q2 2025 Earnings Conference Call July 24, 2025 8:00 AM ET Company Participants Bernard J. Birkett - Senior VP & CFO Eric M.
WST Stock Rises on Q2 Earnings Beat, EPS View Up on Tariff & FX Benefit
West Pharmaceutical's second-quarter top line continues to benefit from revenue growth in its Proprietary Products segment.
West Pharmaceutical Services (WST) Surpasses Q2 Earnings and Revenue Estimates
West Pharmaceutical Services (WST) came out with quarterly earnings of $1.84 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to earnings of $1.52 per share a year ago.
WST Q2 Earnings Preview: Will the Stock's Segmental Edge Hold Up?
West Pharmaceutical targets steady Q2 growth as high-value GLP-1 and SmartDose demand drives segment momentum.
WST Stock Builds on GLP-1 Growth, Annex 1 and Margins in Focus
West Pharmaceutical Services rides on GLP-1 demand and Annex 1 expansion, but margins face pressure from pricing and tariff headwinds.
West Pharmaceutical (WST) Upgraded to Buy: Here's What You Should Know
West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does West Pharmaceutical (WST) Have the Potential to Rally 31.09% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 31.1% in West Pharmaceutical (WST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
West Pharmaceutical Services, Inc. (WST) Q1 2025 Earnings Call Transcript
West Pharmaceutical Services, Inc. (NYSE:WST ) Q1 2025 Earnings Conference Call April 24, 2025 9:00 AM ET Company Participants John Sweeney - Vice President of Investor Relations Eric Green - Chairman, President and Chief Executive Officer Bernard Birkett - Senior Vice President and Chief Financial Officer Conference Call Participants Paul Knight - KeyBanc Larry Solow - CJS Securities Justin Bowers - Deutsche Bank Michael Ryskin - Bank of America David Windley - Jefferies Daniel Markowitz - Evercore ISI Thomas DeBourcy - Nephron Research Doug Schenkel - Wolfe Research Matt Etoch - Stephens Patrick Donnelly - Citi Matthew Larew - William Blair Kyle Crews - UBS Operator Good day, and thank you for standing by. Welcome to the West Pharmaceutical Services First Quarter 2025 Earnings Conference Call.
WST Stock Rises on Q1 Earnings Beat, EPS View Up on Tariff & FX Benefit
West Pharmaceutical's first-quarter top line continues to benefit from revenue growth in its Proprietary Products segment.
West Pharmaceutical Services (WST) Q1 Earnings and Revenues Beat Estimates
West Pharmaceutical Services (WST) came out with quarterly earnings of $1.45 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $1.56 per share a year ago.
